Janux Therapeutics prices $350M public offering of common stock and pre-funded warrants

Janux Therapeutics, Inc.

Priced 5,317,460 shares at $63.00/share and pre-funded warrants for 238,095 shares at $62.999
Gross proceeds expected ~$350M before expenses; funds to advance clinical pipeline and for general purposes
Underwriters granted 30-day option to purchase up to additional 833,333 shares
Offering expected to close Dec 6, 2024; joint book-runners: BofA, TD Cowen, Stifel, Cantor, William Blair

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.